This is single-arm, open-label, safety and feasibility pilot study of ɛ-aminocaproic acid in ICH patients. Consecutive ICH volume with hematoma volume less than 30 mL by ABC/2 method presenting within 3 hours of symptom onset, meeting all inclusion criteria, and without exclusions will be consented and enrolled. Subjects will receive 5 grams of intravenous ɛ-aminocaproic acid over 1 hour, followed by the same at 1 mg/hour for 23 hours. Comupted tomography (CT) head will be done at 24 hours in order to follow hematoma size. Electrocardiogram, lower extremity venous Doppler and NIHSS will also be done at 24 hours. The patient will be followed in the clinic 30-90 days post discharge for functional status.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
Hematoma volume
Time frame: 24 hours
Lower extermity deep vein thrombosis on venous duplex ultrasound
Time frame: 24-48 hours
Evidence of cardiac ischemia on the electrocardiogram
Time frame: 24 hours
National Insitutes of Health Stroke Scale score
Time frame: 24 hours
Modified Rankin Scale score
Time frame: 30 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.